{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:25:55Z","timestamp":1791930355149,"version":"4.3.4"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV-1) infection. A population pharmacokinetic (PK) model was developed for doravirine using pooled data from densely sampled phase 1 trials and from sparsely sampled phase 2b and phase 3 trials evaluating doravirine administered orally as a single entity or as part of a fixed-dose combination of doravirine-lamivudine-tenofovir disoproxil fumarate.<\/jats:p>","DOI":"10.1128\/aac.02502-18","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T11:34:48Z","timestamp":1549971288000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1"],"prefix":"10.1128","volume":"63","author":[{"given":"Ka Lai","family":"Yee","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Ouerdani","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting, Certara, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Claussen","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting, Certara, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"de Greef","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting, Certara, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.070"},{"key":"e_1_3_3_3_2","volume-title":"Pifeltro (doravirine) prescribing information","author":"Merck Sharp & Dohme Corp","year":"2018","unstructured":"Merck Sharp & Dohme Corp. 2018. Pifeltro (doravirine) prescribing information. Merck & Co., Inc., Whitehouse Station, NJ."},{"key":"e_1_3_3_4_2","volume-title":"Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) prescribing information","author":"Merck Sharp & Dohme Corp","year":"2018","unstructured":"Merck Sharp & Dohme Corp. 2018. Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) prescribing information. Merck & Co., Inc., Whitehouse Station, NJ."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19532"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2920"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000876"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01757-16"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3142"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0512-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00326-18"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90166-1"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glr118"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02502-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02502-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:40:32Z","timestamp":1645479632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02502-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1128\/AAC.02502-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02502-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02502-18"}}